Company intelligence / Profile preview

Aurum Biosciences

Glasgow, Scotland, United Kingdomaurumbiosciences.com ↗

Ownership: Private
Employees: ~5
Development stage: Phase 2

Overview

ABL-101 has undergone significant pre-clinical development and has completed early phase 1 and 2a human studies. It has received MHRA clinical trial approval in stroke and is planned for phase 2a trials in stroke, spinal cord injury, and inflammation imaging in 2025[6].

Therapeutic areas: OncologyImmunologyCardiovascularNeurology
Modalities: Oxygen carriers
Industry: Biotech

Drug pipeline

1 asset

ABL-101

Unknown

Beyond the preview

Go deeper on Aurum Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aurum Biosciences.

Explore the full profile